Unicycive Therapeutics, Inc. (UNCY): Total Assets
$49.13M
As of 2025-12-31
$72.03M
As of 2026-06-30
+159.3%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $49.13M | +55.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $31.67M | +123.2% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $14.19M | +403.6% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $2.82M | -85.0% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $18.74M | n/m | 2023-03-31, Balance as of period end |
| 2020-12-31 | $204.0K | n/a | 2022-03-31, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $49.13M | +55.2% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $48.56M | -42.4% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $49.95M | +12.6% |
| NextCure, Inc. (NXTC) | 2025-12-31 | $50.18M | -37.9% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $50.24M | +36.3% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $47.89M | -5.3% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $47.61M | -37.7% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $47.13M | -12.9% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $51.77M | -32.7% |
Compare UNCY, VTGN, COYA, NXTC side by side · Screen every company in Pharmaceutical Preparations ↗